Reduction of CXCR3+CCR6+ CD4+ T Cells and IL-17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Decreased Levels of CXCR3+CCR6+ CD4+ T Cells and IL-17+ RORγt+ CD4+ T Cells During Secukinumab Therapy Correlate with Responsiveness to Subsequent Biologic Treatments in Axial Spondyloarthritis Patients

  • By

  • Addison Pacheco

  • Patricia Remalante-Rayco

  • Nigil Haroon

  • Denis Poddubnyy

  • Robert D. Inman

  • August 29, 2026

Share

Decreased Levels of CXCR3+CCR6+ CD4+ T Cells During Secukinumab Therapy

Overview

This study investigates the correlation between decreased levels of specific CD4+ T cells during secukinumab therapy and the responsiveness to subsequent biologic treatments in axial spondyloarthritis patients.

Background

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that often requires biologic therapies to manage symptoms. A significant proportion of patients do not respond adequately to these treatments.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Secukinumab nonresponders exhibited higher expression of type 1 interferon-regulated genes compared to responders.
  • Increased allograft inflammatory factor 1 may drive heightened type 1 interferon signatures in nonresponders.
  • Immunologic changes during secukinumab therapy could indicate potential responses to subsequent biologic treatments.
  • Response definitions included a ≥50% reduction in BASDAI or a >1.1 decrease in BASDAS, based on established criteria.

Clinical Implications

Understanding the immunologic alterations during secukinumab therapy may assist in predicting patient responses to subsequent biologic treatments.

Conclusion

The study discusses immunologic markers that may inform treatment strategies in axial spondyloarthritis.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
  6. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis | New England Journal of Medicine
  7. Efficacy and Safety of Tumor Necrosis Factor Inhibitors, Interleukin-17 Inhibitors, and Janus Kinase Inhibitors in Patients with Non-Radiographic Axial Spondyloarthritis: A Systematic Review and Network Meta-Analysis - PMC
  8. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
  9. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis | New England Journal of Medicine
  10. Efficacy and Safety of Tumor Necrosis Factor Inhibitors, Interleukin-17 Inhibitors, and Janus Kinase Inhibitors in Patients with Non-Radiographic Axial Spondyloarthritis: A Systematic Review and Network Meta-Analysis - PMC

Original Source(s)

Reduction of CXCR3+CCR6+ CD4+ T Cells and IL-17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy

  • by Addison Pacheco, Patricia Remalante-Rayco, Nigil Haroon, Denis Poddubnyy, Robert D. Inman

  • August 29, 2026

Related Content

Sex-based differences in hip replacement outcomes

A systematic review of more than 2.3 million patients found that women and men had different patterns of postoperative complications and recovery, with age and implant strategy modifying observed differences.

Rheumatoid arthritis tied to birth outcomes

Researchers examine pregnancy outcomes and factors associated with preterm delivery and fetal size.

How clinicians discuss activity may matter

Achievable goals, activity tracking, and social support are among the strategies JAMA researchers recommend for patients with chronic medical conditions.